

ASX Announcement and Media Release

Monday 2 March, 2009

SciGen Limited

SCI GEN SECURE MARKETING LICENSE FOR ALL ITS FORMULATIONS OF HUMAN INSULIN IN CHINA

SciGen Limited ("SciGen") announced today that the company has secured the health registration and marketing authorization for the sale and distribution of SciGen's recombinant human Insulin, SciLin, throughout the People Republic of China.

The long awaited health registration will allow SciGen distributor Shenzhen Meheco and Hefei Life Sciences technology (HLST) to engage in promotional activities thru other distribution partners in China to ensure in-depth coverage in all Chinese provinces. The agreement requires Shenzhen Meheco & HSLT to sell SciGen's recombinant human insulin on an exclusive basis during the 7 years term. Sales are expected to begin in the second quarter of this year.

Shenzhen Meheco and HLST are a well established pharmaceutical company in China with expertise in the Diabetic market, including Insulin.

Recent estimates put the diabetic population in China at 39.8 million with sales expected to reach US\$1 Billion dollars by 2010. Recent clinical trends in China indicate insulin being used more as a first line treatment in Type 2 diabetes.

In China, SciGen expects to generate sales revenues of US\$17 million dollars over the next three years with its recombinant human Insulin. The agreement with Shenzhen Meheco / HSLT, containing minimum order provisions, forms the basis of SciGen expectations. SciGen will purchase Insulin from its contract manufacturing organization and major shareholder Bioton S.A of Poland. Once the fill & finish facility in Hefei, Hanui Province is completed SciGen will source the Active Biologic Substance from Bioton S.A and carry out the fill & finish in its Joint Venture manufacturing facility where SciGen presently hold 51% equity, HSLT 25% and Bioton S.A. 24%.

The chain of events leading to the market authorization is another example of SciGen's demonstrable ability to carry out clinical development, Health regulatory affairs and Business Development in the Asia Pacific Region and to establish partnerships in order to maximise sales and marketing opportunities for SciGen's portfolio of products. Moreover, it continues to consolidate SciGen's revenue streams going forward and adds to financial stability.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988 by its founder, Chairman & CEO Mr. Saul Mashaal. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in the USA, Canada, Australia, S.Korea, Vietnam, Hong Kong and Philippines, distribution channels in Taiwan, China, Malaysia, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

=====ENDS=====

Media enquiries

Saul Mashaal

Founder, Chairman & CEO

Telephone:

Australia : +61 2 9234 1700

Singapore: +65 96305691

USA : +1 612 3097747

Web: www.scigen.com.au